STEM CELL PHARMA INC. (SCPI)
Stem Cell Pharma Inc. (SCPI) is a privately held bio-pharmaceutical company founded in May of 2005, with a capitalization of 10 mm shares, out of which 3.3mm are issued and outstanding.
SCPI owns the world wide rights to an Invention “An Amniotic Membrane Stem Cell Telomerase Enhanced Implant, Manufacturing And Clinical Uses” by Alfred T. Sapse MD (r) its President and Founder. This invention is a novel approach to harvest embryonic type stem cells from the amniotic membrane, a translucid sheet covering placenta. These embryonic cells can potentially repair and if needed rebuild practically all organs, tissues and cells, through a process of differentiation, once introduced in the human body. You would love to read: https://www.fitnesstep1.com/best-spin-bikes-2016-recommendations-and-expert-advice/
The implant had been used with modest to substantial results in the treatment of neuro degenerative diseases such a Multiple Sclerosis (MS), ALS (Lou Gehrig’s Disease), Parkinson’s, in eye diseases (Retinitis Pigmentosa – RP, Usher’s Syndrome – RP plus deafness), Muscular Dystrophy (MDA) including Duchenne’s, children diseases such as Cerebral Palsy (CP) and Epilepsy, autoimmune (Lupus Erythematosus (LE)), and especially in the treatment of symptoms of aging. Clinical studies commenced in the US are now being carried out abroad and some of the results obtained might be used in the United States in the future IND’s submissions to the FDA. There were no reports about infections and rejections or any side effects after the use of the implant.
|1.)||Retinitis Pigmentosa (RP) Center To Open In India. On April 12, 2007 Stem Cell Pharma Inc (SCPI) USA and King Multitech Global Pvt Limited (KMT) India, announced the signing of a Joint Venture (JV) by which a Retinitis Pigmentosa Center, a first of this type in the world will open, subject to regulatory approval in Ludhiana, Punjab, India. This center would accommodate initially 10 patients a day or up to 300 patients a month. India has a population of 400,000 patients with RP, a disease which had no treatment until now.|
|2.)||SCPI is generating a substantial cash flow from the use of our Implant abroad.|
|3.)||Based upon favorable results obtained in a small number of ALS (Amyotrophic lateral sclerosis or Lou Gehrig’s disease) patients. SCPI is actively preparing an Investigative New Drug (IND) application to be submitted shortly to the FDA to request approval to commence clinical studies, using the SCPI Implant in the treatment of ALS. Should the FDA accept our IND application, our project may be granted Orphan Drug Status. Orphan Drug status is granted to drugs that are afflicting less than 200,000 patients (in the US there are 30,000 plus 3-4,000, being added every year. Drug granted orphan drug status are required to go through 1-2 clinical studies only, and fast track approval, should they be found safe and effective.|
|4.)||SCPI had signed an agreement with an US tissue bank by which amniotic membranes will be provided to SCPI for clinical studies in the US and abroad. These amniotic membranes are approved by the FDA after passing all the GMP (Good manufacturing Practices) and GTP (Good Tissue Practices) testing.|
|5.)||Dr. Sapse will be a speaker at the NeuroDrug Conference in London, UK October 23rd – 25th, 2007, titled: “CNS disorders: What the future holds for drugs and Therapies.” This presentation will be on day one Wednesday, Octobers 25th, 2007 at 10:00 am, followed by a panel session: “Key successes in stem cell therapies and where we go from here.” The panelists are Dr. John Sindon – ReNeuron, Dr. Aaron Chuang – Glaxo Smith Kline, and Dr. Alfred T. Sapse – Stem Cell Pharma, Inc.|
|For more details on the 2007 NeuroDrug Conference go to http://www.terrapinn.com/2007/neuro/.|